Skip to main content
Erschienen in: Strahlentherapie und Onkologie 4/2015

01.04.2015 | Original article

Dose-dependent changes in renal 1H-/23Na MRI after adjuvant radiochemotherapy for gastric cancer

verfasst von: Stefan Haneder, MD, Johannes Michael Budjan, MD, Stefan Oswald Schoenberg, MD, Simon Konstandin, PhD, Lothar Rudi Schad, PhD, Ralf Dieter Hofheinz, MD, Veronika Gramlich, MSc, Frederik Wenz, MD, Frank Lohr, MD, Judit Boda-Heggemann, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Combined radiochemotherapy (RCT) for gastric cancer with three-dimensional conformal radiotherapy (3D-CRT) results in ablative doses to the upper left kidney, while image-guided intensity-modulated radiotherapy (IG-IMRT) allows kidney sparing despite improved target coverage. Renal function in long-term gastric cancer survivors was evaluated with 3T functional magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) and 23Na imaging.

Patients and methods

Five healthy volunteers and 13 patients after radiotherapy were included: 11×IG-IMRT; 1×3D-CRT; 1× “positive control” with stereotactic body radiotherapy (SBRT) of a metastasis between the spleen/left kidney. Radiation doses were documented for the upper/middle/lower kidney subvolumes. Late toxicity was evaluated based on CTC criteria, questionnaire, and creatinine values. Morphological sequences, DWI images, and 23Na images were acquired using a 1H/23Na-tuned body-coil before/after intravenous water load (WL). Statistics for [23Na] (concentration) and apparent diffusion coefficient (ADC) values were calculated for upper/middle/lower renal subvolumes. Corticomedullary [23Na] gradients and [23Na] differences after WL were determined.

Results

No major morphological alteration was detected in any patient. Minor scars were observed in the cranial subvolume of the left kidney of the 3D-CRT and the whole kidney of the control SBRT patient. All participants presented a corticomedullary [23Na] gradient. After WL, a significant physiological [23Na] gradient decrease (p < 0.001) was observed in all HV and IG-IMRT patients. In the cranial left kidney of the 3D-CRT patient and the positive control SBRT patient, the decrease was nonsignificant (p = 0.01, p = 0.02). ADC values were altered nonsignificantly in all renal subvolumes (all participants). Renal subvolumes with doses ≥ 35 Gy showed a reduced change of the [23Na] gradient after WL (p = 0.043). No participants showed clinical renal impairment.

Conclusions

Functional parameters of renal 23Na MRI after gastric IG-IMRT are identical to those of healthy volunteers, in contrast to renal subvolumes after ablative doses in the control and 3D-CRT patient. While kidney doses to the cortex below 20–25 Gy in fractional doses of ~ 1 Gy in IG-IMRT (combined with intensified chemotherapy) do not seem to cause significant MRI morphological or functional alterations, doses of > 35 Gy in 1.5–2 Gy fractions clearly result in impairment.
Literatur
1.
Zurück zum Zitat Boda-Heggemann J, Mennemeyer P, Wertz H et al (2009) Accuracy of ultrasound-based image guidance for daily positioning of the upper abdomen: an online comparison with cone beam CT. Int J Radiat Oncol Biol Phys 74:892–897CrossRefPubMed Boda-Heggemann J, Mennemeyer P, Wertz H et al (2009) Accuracy of ultrasound-based image guidance for daily positioning of the upper abdomen: an online comparison with cone beam CT. Int J Radiat Oncol Biol Phys 74:892–897CrossRefPubMed
2.
Zurück zum Zitat Boda-Heggemann J, Hofheinz RD, Weiss C et al (2009) Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. Int J Radiat Oncol Biol Phys 75:1187–1195CrossRefPubMed Boda-Heggemann J, Hofheinz RD, Weiss C et al (2009) Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. Int J Radiat Oncol Biol Phys 75:1187–1195CrossRefPubMed
3.
Zurück zum Zitat Boda-Heggemann J, Lohr F, Wenz F, Flentje M, Guckenberger M (2011) kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 187:284–291CrossRefPubMed Boda-Heggemann J, Lohr F, Wenz F, Flentje M, Guckenberger M (2011) kV cone-beam CT-based IGRT: a clinical review. Strahlenther Onkol 187:284–291CrossRefPubMed
4.
Zurück zum Zitat Boda-Heggemann J, Guckenberger M, Ganswindt U et al (2012) Image-guided radiation therapy. Der Radiologe 52:213–221CrossRefPubMed Boda-Heggemann J, Guckenberger M, Ganswindt U et al (2012) Image-guided radiation therapy. Der Radiologe 52:213–221CrossRefPubMed
5.
Zurück zum Zitat Boda-Heggemann J, Weiss C, Schneider V et al (2013) Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 189:417–423CrossRefPubMed Boda-Heggemann J, Weiss C, Schneider V et al (2013) Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 189:417–423CrossRefPubMed
6.
Zurück zum Zitat Dikken JL, van Sandick JW, Maurits Swellengrebel HA et al (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11:329CrossRefPubMedCentralPubMed Dikken JL, van Sandick JW, Maurits Swellengrebel HA et al (2011) Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 11:329CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Fakhrian K, Ordu AD, Lordick F et al (2014) Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: More than 20 years’ experience at a single institution. Strahlenther Onkol (epub ahead of print) Fakhrian K, Ordu AD, Lordick F et al (2014) Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: More than 20 years’ experience at a single institution. Strahlenther Onkol (epub ahead of print)
8.
Zurück zum Zitat Guckenberger M, Meyer J, Wilbert J, Baier K, Sauer O Flentje M (2007) Precision of image-guided radiotherapy (IGRT) in six degrees of freedom and limitations in clinical practice. Strahlenther Onkol 183:307–313CrossRefPubMed Guckenberger M, Meyer J, Wilbert J, Baier K, Sauer O Flentje M (2007) Precision of image-guided radiotherapy (IGRT) in six degrees of freedom and limitations in clinical practice. Strahlenther Onkol 183:307–313CrossRefPubMed
9.
Zurück zum Zitat Haneder S, Konstandin S, Morelli JN et al (2011) Quantitative and qualitative 23Na MR imaging of the human kidneys at 3 T: before and after a water load. Radiology 260:857–865CrossRefPubMed Haneder S, Konstandin S, Morelli JN et al (2011) Quantitative and qualitative 23Na MR imaging of the human kidneys at 3 T: before and after a water load. Radiology 260:857–865CrossRefPubMed
10.
Zurück zum Zitat Haneder S, Juras V, Michaely HJ et al (2013) In vivo sodium (Na) imaging of the human kidneys at 7 T: preliminary results. Eur Radiol 24(2):494–501 Haneder S, Juras V, Michaely HJ et al (2013) In vivo sodium (Na) imaging of the human kidneys at 7 T: preliminary results. Eur Radiol 24(2):494–501
11.
Zurück zum Zitat Haneder S, Kettnaker P, Konstandin S et al (2013) Quantitative in vivo (23)Na MR imaging of the healthy human kidney: determination of physiological ranges at 3.0 T with comparison to DWI and BOLD. Magma 26:501–509CrossRefPubMed Haneder S, Kettnaker P, Konstandin S et al (2013) Quantitative in vivo (23)Na MR imaging of the healthy human kidney: determination of physiological ranges at 3.0 T with comparison to DWI and BOLD. Magma 26:501–509CrossRefPubMed
12.
Zurück zum Zitat Haneder S, Konstandin S, Morelli JN, Schad LR, Schoenberg SO, Michaely HJ (2013) Assessment of the renal corticomedullary (23)Na gradient using isotropic data sets. Acad Radiol 20:407–413CrossRefPubMed Haneder S, Konstandin S, Morelli JN, Schad LR, Schoenberg SO, Michaely HJ (2013) Assessment of the renal corticomedullary (23)Na gradient using isotropic data sets. Acad Radiol 20:407–413CrossRefPubMed
13.
Zurück zum Zitat Haneder S, Michaely HJ, Schoenberg SO et al (2012) Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional 1 H-MRI and 23Na-MRI. Strahlenther Onkol 188:1146–1154CrossRefPubMed Haneder S, Michaely HJ, Schoenberg SO et al (2012) Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional 1 H-MRI and 23Na-MRI. Strahlenther Onkol 188:1146–1154CrossRefPubMed
14.
Zurück zum Zitat Haneder S, Michaely HJ, Konstandin S et al (2013) 3 T Renal Na-MRI: effects of desmopressin in patients with central diabetes insipidus. Magma 27(1):47–52. Haneder S, Michaely HJ, Konstandin S et al (2013) 3 T Renal Na-MRI: effects of desmopressin in patients with central diabetes insipidus. Magma 27(1):47–52.
15.
Zurück zum Zitat Hofheinz RD, Wenz F, Lukan N et al (2009) Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73:142–147CrossRefPubMed Hofheinz RD, Wenz F, Lukan N et al (2009) Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial. Int J Radiat Oncol Biol Phys 73:142–147CrossRefPubMed
16.
Zurück zum Zitat Huber K (2013) Cancer of the esophagus and gastroesophageal junction: improved survival with neoadjuvant radiochemotherapy. Strahlenther Onkol 189:161–162CrossRefPubMed Huber K (2013) Cancer of the esophagus and gastroesophageal junction: improved survival with neoadjuvant radiochemotherapy. Strahlenther Onkol 189:161–162CrossRefPubMed
17.
Zurück zum Zitat Jansen EP, Boot H, Saunders MP et al (2007) A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 69:1424–1428CrossRefPubMed Jansen EP, Boot H, Saunders MP et al (2007) A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 69:1424–1428CrossRefPubMed
18.
Zurück zum Zitat Jansen EP, Saunders MP, Boot H et al (2007) Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 67:781–785CrossRefPubMed Jansen EP, Saunders MP, Boot H et al (2007) Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys 67:781–785CrossRefPubMed
19.
Zurück zum Zitat Lee J, Lim do H, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268–273CrossRefPubMed Lee J, Lim do H, Kim S et al (2012) Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 30:268–273CrossRefPubMed
21.
Zurück zum Zitat Lohr F, Dobler B, Mai S et al (2003) Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 179:557–563CrossRefPubMed Lohr F, Dobler B, Mai S et al (2003) Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT. Strahlenther Onkol 179:557–563CrossRefPubMed
22.
Zurück zum Zitat Macdonald JS, Fleming TR, Peterson RF et al (1995) Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol 2:488–494CrossRefPubMed Macdonald JS, Fleming TR, Peterson RF et al (1995) Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol 2:488–494CrossRefPubMed
23.
Zurück zum Zitat Michaely HJ, Metzger L, Haneder S, Hansmann J, Schoenberg SO, Attenberger UI (2012) Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int 81:684–689CrossRefPubMed Michaely HJ, Metzger L, Haneder S, Hansmann J, Schoenberg SO, Attenberger UI (2012) Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int 81:684–689CrossRefPubMed
24.
Zurück zum Zitat Nagel AM, Laun FB, Weber MA, Matthies C, Semmler W, Schad LR (2009) Sodium MRI using a density-adapted 3D radial acquisition technique. Magn Reson Med 62:1565–1573CrossRefPubMed Nagel AM, Laun FB, Weber MA, Matthies C, Semmler W, Schad LR (2009) Sodium MRI using a density-adapted 3D radial acquisition technique. Magn Reson Med 62:1565–1573CrossRefPubMed
25.
Zurück zum Zitat Ohri N, Garg MK, Aparo S et al (2013) Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 86:330–335CrossRefPubMed Ohri N, Garg MK, Aparo S et al (2013) Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 86:330–335CrossRefPubMed
26.
Zurück zum Zitat Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333CrossRefPubMed Smalley SR, Benedetti JK, Haller DG et al (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327–2333CrossRefPubMed
27.
Zurück zum Zitat Thoeny HC, Zumstein D, Simon-Zoula S et al (2006) Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: initial experience. Radiology 241:812–821CrossRefPubMed Thoeny HC, Zumstein D, Simon-Zoula S et al (2006) Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: initial experience. Radiology 241:812–821CrossRefPubMed
28.
Zurück zum Zitat Welz S, Hehr T, Kollmannsberger C, Bokemeyer C, Belka C Budach W (2007) Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. Int J Radiat Oncol Biol Phys 69:1429–1435CrossRefPubMed Welz S, Hehr T, Kollmannsberger C, Bokemeyer C, Belka C Budach W (2007) Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancer. Int J Radiat Oncol Biol Phys 69:1429–1435CrossRefPubMed
29.
Zurück zum Zitat Wieland P, Dobler B, Mai S et al (2004) IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 59:1236–1244CrossRefPubMed Wieland P, Dobler B, Mai S et al (2004) IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int J Radiat Oncol Biol Phys 59:1236–1244CrossRefPubMed
30.
Zurück zum Zitat Xu X, Fang W, Ling H, Chai W Chen K (2010) Diffusion-weighted MR imaging of kidneys in patients with chronic kidney disease: initial study. Eur Radiol 20:978–983CrossRefPubMed Xu X, Fang W, Ling H, Chai W Chen K (2010) Diffusion-weighted MR imaging of kidneys in patients with chronic kidney disease: initial study. Eur Radiol 20:978–983CrossRefPubMed
Metadaten
Titel
Dose-dependent changes in renal 1H-/23Na MRI after adjuvant radiochemotherapy for gastric cancer
verfasst von
Stefan Haneder, MD
Johannes Michael Budjan, MD
Stefan Oswald Schoenberg, MD
Simon Konstandin, PhD
Lothar Rudi Schad, PhD
Ralf Dieter Hofheinz, MD
Veronika Gramlich, MSc
Frederik Wenz, MD
Frank Lohr, MD
Judit Boda-Heggemann, MD, PhD
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 4/2015
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0787-x

Weitere Artikel der Ausgabe 4/2015

Strahlentherapie und Onkologie 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.